Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Knight Therapeutics Inc (GUD.TO)

Knight Therapeutics Inc (GUD.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 578,695
  • Shares Outstanding, K 101,170
  • Annual Sales, $ 328,199 K
  • Annual Income, $ -16,835 K
  • 60-Month Beta 0.29
  • Price/Sales 1.90
  • Price/Cash Flow 17.10
  • Price/Book 0.77
Trade GUD.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings $-0.23 on N/A
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.23 +10.71%
on 04/01/24
5.95 -2.69%
on 04/11/24
+0.52 (+9.87%)
since 03/22/24
3-Month
5.21 +11.13%
on 03/21/24
5.95 -2.69%
on 04/11/24
+0.15 (+2.66%)
since 01/22/24
52-Week
4.35 +33.10%
on 10/23/23
5.95 -2.69%
on 04/11/24
+0.97 (+20.12%)
since 04/21/23

Most Recent Stories

More News
Stocks in play: Knight Therapeutics Inc.

Will release its fourth-quarter and year-end 2023 financial results on Thursday, March 21, prior to ...

GUD.TO : 5.79 (+1.22%)
Stocks in play: Knight Therapeutics Inc.,

Announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. ...

GUD.TO : 5.79 (+1.22%)
Stocks in play: Knight Therapeutics Inc.

Has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc., a biopharmaceutical ...

GUD.TO : 5.79 (+1.22%)
Stocks in play: Knight Therapeutics Inc.

Reported financial results for its third quarter ended September 30, 2023. All currency amounts are ...

GUD.TO : 5.79 (+1.22%)
Stocks in play: Knight Therapeutics Inc.

Has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). ...

GUD.TO : 5.79 (+1.22%)
Stocks in play: Knight Therapeutics Inc.

Reported financial results for its second quarter ended June 30, 2023. Revenues were $89.905 million, ...

GUD.TO : 5.79 (+1.22%)
Stocks in play: Knight Therapeutics Inc.

Announced today acceptance by the Toronto Stock Exchange of the Company's Notice of Intention to Make ...

GUD.TO : 5.79 (+1.22%)
Stocks in play: Knight Therapeutics Inc.

Will release its third-quarter 2022 financial results on Thursday, November 10, prior to market opening. ...

GUD.TO : 5.79 (+1.22%)
Stocks in play: Knight Therapeutics Inc

Announced it placed No. 22 on the 2022 Report on Business ranking of Canada’s Top Growing Companies. ...

GUD.TO : 5.79 (+1.22%)
Stocks in play: Knight Therapeutics Inc.

Reported financial results for its second quarter ended June 30, 2022. Revenues were $75,820, an increase ...

GUD.TO : 5.79 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin...

See More

Key Turning Points

3rd Resistance Point 5.90
2nd Resistance Point 5.84
1st Resistance Point 5.82
Last Price 5.79
1st Support Level 5.74
2nd Support Level 5.68
3rd Support Level 5.66

See More

52-Week High 5.95
Last Price 5.79
Fibonacci 61.8% 5.34
Fibonacci 50% 5.15
Fibonacci 38.2% 4.96
52-Week Low 4.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar